GALDERMA
Galderma today announced that the Swedish Medical Products Agency (Läkemedelsverket) issued key manufacturing license updates that will allow the company to pursue its ambitious growth and innovation roadmap.
The license updates, issued following the agency’s good manufacturing practices (GMP) inspection of Galderma’s center of excellence in Uppsala, Sweden, enable Galderma to manufacture and perform bioanalytical testing on RelabotulinumtoxinA (QM1114). One of Galderma’s key innovation pipeline assets in Injectable Aesthetics, RelabotulinumtoxinA is a next-generation liquid neuromodulator in Injectable Aesthetics developed using Galderma’s proprietary PEARL™ technology. This technology preserves the molecule’s integrity, resulting in a highly active, complex-free botulinum toxin A.
“Our commitment to leading innovation in dermatology is reflected in our high-performance operations. These new license updates granted by the Swedish authorities reflect Galderma’s skills and the capacities we are building to support our rapid growth trajectory. As we work to extend our category leadership globally, these new capabilities will increase Galderma’s autonomy to manufacture and commercialize the next generation of scientifically differentiated innovations in dermatology.”
ADRIAN MURPHY HEAD OF GLOBAL OPERATIONS GALDERMA
|
Galderma’s center of excellence in Uppsala is one of the company’s four state-of-the-art manufacturing and R&D facilities around the world. Galderma is currently expanding this site in response to growing global demand for science-based premium dermatology solutions. The new facility—scheduled for completion by the end of 2025—will be strategically positioned to cater to the higher demand for injectable aesthetics treatments worldwide and the development of upcoming products. With a modular design that allows for seamless further expansion in the future, this forward-looking approach aligns with both Galderma’s growth strategy and its environment, social and governance (ESG) roadmap.
About RelabotulinumtoxinA (QM1114)
Developed by Galderma, RelabotulinumtoxinA is a highly active, innovative, complex-free and ready-to-use liquid botulinum toxin A with a proprietary strain. Manufactured using a unique state-of-the-art process, it is designed as a liquid. This avoids the need to reconstitute from powder and thus eliminates the variability, errors and risks associated with reconstitution, which would be expected to improve the consistency of results. RelabotulinumtoxinA is currently being investigated globally, with a view to expanding its neuromodulator portfolio – part of the broadest injectable aesthetics portfolio on the market.
About Galderma
Galderma (SIX: GALD) is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ—the skin—meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618347979/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HumanX Amsterdam Reveals First 100 Speakers, Bringing Global AI Powerhouses to Europe13.1.2026 14:00:00 CET | Press release
Anton Osika (Lovable), May Habib (Writer), Jan Oberhauser (n8n) & Eléonore Crespo (Pigment) headline a diverse lineup spanning AI innovation and enterprise adoption HumanX, the global AI summit for executives and innovators, today unveiled its first 100 speakers and opened registration for HumanX Amsterdam, taking place 22–24 September 2026 at The RAI. Built by the team behind Money20/20, Shoptalk, and HLTH, HumanX Amsterdam brings the proven formula of its #1 U.S. flagship event and ecosystem gathering to Europe. The event convenes over 2,500 senior leaders focused on moving beyond the hype to drive practical, responsible AI implementation across industries. Speakers Leading the Conversation The first 100 speakers include AI company founders such as Anton Osika (Lovable), Jan Oberhauser (n8n), May Habib (Writer), Arvind Jain (Glean), and Jarek Kutylowski (DeepL), alongside executives scaling AI in the enterprise, including Clay Bavor (Sierra), Des Traynor (Intercom), and Eléonore Cres
GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 14:00:00 CET | Press release
The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are
Wolfspeed Achieves 300mm Silicon Carbide (SiC) Technology Breakthrough13.1.2026 14:00:00 CET | Press release
300mm SiC Technology, Enabling Scalable Platforms for AI Infrastructure, AR/VR, and Advanced Power DevicesAnnouncement highlights:Strategic Technology Milestone – Wolfspeed has produced a single crystal 300mm (12-inch) silicon carbide wafer, representing a major advancement in the evolution of silicon carbide technology and a critical enabler for emerging applications. Technology leadership for Next-Gen Applications – Backed by one of the industry’s largest and most foundational silicon carbide IP portfolios, with over 2,300 issued and pending patents worldwide, Wolfspeed is accelerating the commercialization of 300mm technology to power next-generation platforms including AI infrastructure, augmented reality/virtual reality (AR/VR) and advanced power devices. Strengthening U.S. Semiconductor Leadership & Supply Chain Resilience –The company’s vertically integrated supply chain, from crystal growth to advanced packaging, supports national goals around compound semiconductor independenc
ExaGrid’s FY 2025 Results—A Record Quarter and a Record Year for Company13.1.2026 14:00:00 CET | Press release
ExaGrid reports 20 consecutive quarters of positive P&L, EBITDA, and Free Cash Flow ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that it had record bookings and record revenue in the fourth quarter ending December 31, 2025, and had a record-year for bookings and revenue for 2025. ExaGrid broke many records in the quarter (Q4 2025), including: Record overall revenue and bookings Record revenue and bookings for new customers Record revenue and bookings for existing customer repeat orders Record 202 new logo customers in the quarter Record 88 six-figure new logo customers 3 seven-figure new logo customer deals In addition, ExaGrid had a record bookings and revenue year in 2025 and remained P&L, EBITDA, and free cash flow positive for the 20th consecutive quarter. The company is 100
Armis Secures Italy’s Primary Public Healthcare Provider for the City of Naples as Cyber Threats Increase13.1.2026 14:00:00 CET | Press release
Armis Centrix™ provides immediate and detailed insights on network-connected assets, supporting compliance with national and European regulatory requirements Armis, the cyber exposure management & security company, today announced that ASL Napoli 1 Centro, Italy’s primary public healthcare provider for the City of Naples, is securing its attack surface using Armis Centrix™, the Armis Cyber Exposure Management Platform. Prior to working with Armis, ASL Napoli 1 Centro did not have the tools or capabilities to monitor physical and virtual assets in real time, which posed a challenge for its security and compliance. Armis Centrix™ was deployed with a clear goal: to provide ASL Napoli 1 Centro with a comprehensive, real-time view of its connected biomedical inventory and the associated risks to the overall environment. “Time-to-value was practically immediate; Armis began delivering valuable information as soon as the system was activated and connected to our internal network,” said Fulvio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom